Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

COMPASS Pathways Plc - American Depository Shares (NQ: CMPS )

7.840 -0.220 (-2.73%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 9, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 129,698
Open 8.020
Bid (Size) 7.770 (2)
Ask (Size) 8.040 (70)
Prev. Close 8.060
Today's Range 7.760 - 8.100
52wk Range 6.970 - 21.50
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Major Psychedelic Compound-Based Research & Development Stocks: June Update
Psychedelic Drug Stocks Index has been revamped with the removal of Cybin (CYBN) which has dropped below $100M in market capitalization leaving 6 constituents in the Index 
Via Talk Markets
Largest Phase 3 Clinical Trial on Psilocybin Gets Underway
Via Investor Brand Network

Performance

YTD
+1.55%
+1.55%
1 Month
-7.98%
-7.98%
3 Month
-3.09%
-3.09%
6 Month
-25.48%
-25.48%
1 Year
-14.60%
-14.60%

More News

Read More
Numinus' Clinical Arm To Lead Enrollment Site For MindMed's Phase 2b LSD Study
Via Benzinga
May Summary Of Largest Psychedelic Compound-Based Drug Stock Performances
Via Talk Markets
Psyched: LSD Microdosing For Depression, DMT For Anxiety, MDMA Octopuses And More
Via Benzinga
Expert Ratings for Compass Pathways
Via Benzinga
Compass Pathways: Q1 Earnings Insights
Via Benzinga
Earnings Preview: Compass Pathways
Via Benzinga
Numinus' Clinical Site Joins Compass' Phase 3 Program On Psilocybin Therapy For TRD
Via Benzinga
Trial Gives Cancer Patients 18 Months Of Robust Benefits After One Psilocybin Session
Via Benzinga
Link Between Cancer And Psilocybin: Research On This Palliative Promise
Via Benzinga
Psyched: $20M Research Fund, LSD Microdosing For Cancer, MEAI Enters Clinical Stage, Reform Update & More
Via Benzinga
COMPASS Pathways Reports Q1 2023: Financials, Commercial Groundwork And Ongoing Phase 3 Trials
Via Benzinga
Atai Life Sciences Q1 2023 Results, Pipeline Update On DMT And Psilocybin Clinical Trials
Via Benzinga
Compass Pathways Plc (CMPS) Q1 2023 Earnings Call Transcript
Via The Motley Fool
COMPASS Pathways Announces First Quarter 2023 Financial Results and Business Highlights
From COMPASS Pathways
Via GlobeNewswire
Psyched: Psychedelics Reimbursement, Amanita Muscaria Boom, $53M Material Breach Lawsuit & More
Via Benzinga
This Regulatory Change Means Psychedelic Stocks Are One Step Closer to Being a Buy. Here's Why
Via The Motley Fool
EXCLUSIVE: AMA Moves Toward Psychedelic Therapy Reimbursement, Filing A Gap In Regulations
Via Benzinga
American Medical Association to Issue First New Code for Psychedelic Therapies
From COMPASS Pathways
Via GlobeNewswire
April Psychedelic Drug Stocks Recap: The Ups And Downs
Via Talk Markets
Seelos Therapeutics, Compass Pathways Among Top Psychedelic Movers Of Today
Via Benzinga
Seelos Therapeutics, ATAI Life Sciences Among Top Psychedelic Movers Of Today
Via Benzinga
After Falling 60% in 1 Year, Is Atai Life Sciences Stock Still a Buy?
Via The Motley Fool
Cybin, Mind Medicine Among Top Psychedelic Movers Of Today
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.